Introduction: Biologic therapies are efficacious but costly. A number of health economic
medicine. Where opinions differed, we sought to identify a research agenda that would generate the evidence needed to reach consensus. Results: We gained consensus in four areas of model development: initial response to treatment; long-term disease progression; lifetime costs and benefits; and model structure. Consensus was also achieved on some key parameters such as choices of outcome measures, methods for extrapolation beyond trial data, and treatment switching. A research agenda to support further consensus was also identified. Conclusion: Consensus guidance that fully reflects current evidence and clinical understanding was gained successfully. In addition, research needs have been identified.
Such guidance can be updated as evidence develops and policy questions change and need not be prescriptive as long as deviations from consensus are clearly explained and justified.
INTRODUCTION
Biologic therapies represent a recent addition to treatments for inflammatory joint diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). While their efficacy has been established in a number of clinical trials and cost-effectiveness demonstrated in a number of assessments [1, 2] , the evidence base is still associated with substantial uncertainty, and this poses a considerable challenge for decision-making in defining the role of different agents in the sequence of disease-modifying drugs used to manage these chronic diseases. A workshop to explore these challenges took place in 2010, the proceedings of which were disseminated in a series of papers [3] [4] [5] [6] [7] [8] [9] [10] . A key finding of the workshop was that, despite the importance of economic models in guiding policy on the adoption of biologic therapies, there was no clear consensus on how the models should be structured, how they should be informed from data, or even which data were the most appropriate.
Moreover, the differences between the models were sufficiently substantial to lead to contradictory recommendations. If consensus views were available beforehand on the desirable properties of the economic model, and the data sources that should inform it, this would assist model development and review to inform future policy decisions. With this in mind, a Consensus Working Party on decision models for biologic therapies in RA and PsA was formed to identify the current scope for consensus, and identify gaps in the evidence base where further research is needed to support future consensus.
METHODS
The working party was set up to bring together (Table 1) . Their remit was to: (1) frame and clarify the issues for which consensus needs to be sought; (2) set out, where possible, initial recommendations for consensus approaches for models, based on sound methodology, clinical judgment, and decision-maker preferences; and This article is based on the discussions of the Consensus Working Party and does not involve any new studies of human or animal subjects performed by any of the authors. 
RESULTS

Modeling the Initial Response to Treatment
Summary of Consensus View
• Disease Activity Score 28 (DAS28) should be used to represent initial response to treatment in RA.
• Models should reflect current guidelines and withdraw treatment from patients with an inadequate response. The timing of this should follow current clinical guidelines, to aid comparison of results among models, although the impact of alternative stopping rules can be explored in sensitivity analysis.
• Currently, robust evidence for effect modification has not been identified, and effect modification should not be included in evidence synthesis of initial response treatment effects.
• Models should represent the cause for discontinuation of treatment (i.e., lack of response or adverse events).
• Estimates of short-term response to biologics should be based on all relevant trials and derived using formal evidence synthesis methodology that respects randomization.
Mapping functions should be used within the synthesis so that trials can be included even if they do not report DAS28.
• Mapping functions should also be used to relate changes in DAS28 to changes in the measure used to represent long-term disease progression.
• Response rates to the non-biologic comparator can be based on pooling control arms from biologic trials, although the comparability of trial and decision populations should be considered.
• • DAS28 most closely reflects clinical benefit of treatment in the short term.
• Relatively small changes are still clinically meaningful to patients.
• It is an absolute scale (although the related European League Against Rheumatism [EULAR] response categories depend on both absolute change in DAS and DAS at endpoint).
• It is particularly appropriate for the UK, where it has received support from clinical experts in previous NICE appraisals, and is the basis of current NICE guidance.
American College of Rheumatology (ACR) 20/50/70 was considered problematic because it is a relative measure. However, given that it is commonly reported there is a clear need for mapping functions to characterize the relationship between the two measures, as it is not appropriate to exclude relevant studies solely because they do not report DAS28. For PsA, both outcomes (skin and joint symptoms) with the latter is potential selection bias. Where data is weak, expert elicitation could guide adjustments related to changes in position within the sequence. However, in the absence of convincing evidence for effect modification, the simpler approach of using unadjusted treatment effects is preferable, particularly if an absolute scale such as DAS28 is used for response.
Estimating the Baseline Response in the Comparator
Treatment For modeling purposes, relative treatment effects need to be applied to the absolute proportion of (DAS28) responders that would be seen if a conventional DMARD was given instead of a biologic at the relevant point in the sequence. The absolute rate from the control arm of a biologic trial has often been used for this purpose, as have absolute rates from trials of conventional
DMARDs. An alternative would be to use registry data. The latter would match the required patient profile most closely, but would be vulnerable to issues such as selection bias. Therefore, the approach of pooling control arms from trials with populations similar to the decision population was preferred. [16] . Systematic reviews of sequential biologic therapy have also assessed the impact on the efficacy of a second biologic of having experiences adverse events on the first biologic [17] . This evidence base needs to be collated, updated and synthesized to inform the consensus model.
Modeling Adverse Events in the Initial
Modeling the Long-Term Treatment Phase
Summary of Consensus View
• HAQ should be used to represent disease progression, although a multidimensional measure which includes pain should be considered for mapping disease progression to health utilities.
• The source for mappings used between outcome measures should be clearly stated and justified, and be consistent with current applied and methodological research.
• Survival models may be used to extrapolate beyond the follow-up period of data on the duration of successful long-term treatment.
All relevant data should be used to fit such models; this may include open-label trial follow-up and registry data. However, treatment duration differences between biologics should not be assumed based on observational data alone.
• Assumed rates of HAQ progression should be consistent with observations from longitudinal data.
• Models should distinguish between adverse events and loss of efficacy as reasons for treatment withdrawal.
• The rebound in disease progression on treatment withdrawal should be evidence-based as far as possible. Where multiple scenarios are consistent with the available evidence, the impact of alternative plausible assumptions should be explored through sensitivity analysis.
Outcome of Workshop Discussions
HAQ has been widely used in models to represent disease progression, for historical reasons. Several mapping algorithms between HAQ and quality of life (QoL) measures (e.g., EQ5D) have been developed and used in existing models [18, 19] . However, algorithms for mapping between outcome measures such as HAQ and EQ5D are an area of active research [20] , and the most appropriate algorithm for use in decision models may change over time. For example, recent research has suggested that pain has an important influence on QoL in patients with RA, independent of HAQ [24] .
Therefore, models could in future use a multidimensional (HAQ and pain) outcome measure for disease progression. This will first involve identifying the appropriate data sources, which may include registries and/ or IPD from trials (if available). The appropriate method for deriving mapping algorithms from this data will then need to be identified. For PsA, data collected by the GRACE study may provide information to map combined joint, skin and pain symptoms to QoL scores. 
Estimating Lifetime Costs and Benefits
Summary of Consensus View
• Models should allow for an association between disease severity and mortality.
• Models should adopt the decision-maker's chosen perspective for costs included. This may involve assuming health care utilization to be a function of disease severity.
Outcome of Workshop Discussions
There is evidence to suggest disease severity has an impact on age-adjusted mortality risk, but not to suggest that choice of treatment has any additional influence on mortality. [24] , and their analysis included covariates such as disease duration and severity.
Additional research would identify the full current evidence base and use this to derive the consensus relationship, either through synthesis of multiple evidence sources or establishing clinical consensus on the most appropriate data source.
Structural Modeling Approaches
Summary of Consensus View
• Models should be able to represent response for each biologic therapy in a sequence, but
do not need to model individual post-biologic conventional DMARDs.
• Individual patient models have several advantages when representing RA and PsA patient histories, but the merits of cohort modeling approaches should also be explored.
Outcome of Workshop Discussions
Models should have the flexibility to explore alternative positions for biologics within the sequence of treatments. While there may be benefit in modeling specific DMARD sequences once biologic therapies have been exhausted, the group felt that treatments have limited effects at this stage in practice. Therefore, it is preferable not to explicitly model sequences of conventional DMARDs following biologic therapy, unless data on such patients becomes available that credibly challenges this view.
The group noted that both cohort and individual sampling approaches have been adopted by previous models, and there were divergent views over the relative merits of these approaches. Guidance exists in the literature on factors which should influence the choice of model type [25, 26] ; as a general principle, models should be as simple as possible whilst remaining consistent with the underlying decision problem and theory of disease [27] . However, the appropriate model structure for the evaluation of biologics in arthritis has not been definitively established in the literature, and remains a question of both practical and methodological interest.
Current Available Evidence and Further Research Needs
Given the alternative approaches to model structure in existing models, future research should involve developing models that follow the consensus approach as closely as possible whilst adopting alternative structures, to evaluate how closely each model structure is able to follow the consensus approach and the impact of structure on model results. to fairly present the benefits of their product, and the latter might wish to follow their own academic opinion on the appropriate modeling approach for a specific policy question. However, if they were encouraged to set out how their models differed from the consensus approach, and present the impact of this deviation on their results, the resulting transparency would enhance the credibility of recommendations derived from those models, and help decision-makers understand the reasons behind any differences in findings between models.
DISCUSSION
One limitation of this consensus is that the working group consisted solely of UK-based clinicians, models and regulators. Health technology assessment clearly has aspects that are country-specific, and this may mean that certain elements of our consensus would need to be adapted to other contexts. However, the structures we have followed, and many of our findings, are relevant internationally. Our work also provides a case study of a process that can easily be extended to support decision-making in other disease areas. The process of developing consensus, and identifying its current limits, has the added benefit of highlighting areas where further research is most needed to support reimbursement decisions.
ACKNOWLEDGMENTS
The workshops referred to in this manuscript 
